<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020124</url>
  </required_header>
  <id_info>
    <org_study_id>000088</org_study_id>
    <secondary_id>00-C-0088</secondary_id>
    <secondary_id>CDR0000067718</secondary_id>
    <nct_id>NCT00020124</nct_id>
    <nct_alias>NCT00004636</nct_alias>
  </id_info>
  <brief_title>Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs</brief_title>
  <official_title>Phase I and Clinical Pharmacologic Study of Inhaled Doxorubicin in Adults With Advanced Solid Tumors Affecting the Lungs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving drugs in different ways may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients&#xD;
      who have advanced solid tumors affecting the lungs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and phase II dose of inhaled doxorubicin in&#xD;
           patients with advanced solid tumors affecting the lungs.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of inhaled doxorubicin in blood in these patients.&#xD;
&#xD;
        -  Determine the relationship between pharmacodynamic parameters and toxic effects of this&#xD;
           regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive inhaled doxorubicin every 3 weeks for up to 3 doses. Patients with stable or&#xD;
      responding disease may receive additional doses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of doxorubicin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 3 weeks and 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 33 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <condition>Malignant Mesothelioma</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven advanced cancer not curable by standard chemotherapy,&#xD;
             radiotherapy, or surgery&#xD;
&#xD;
               -  Clinical evidence of primary lung or tracheal cancer OR&#xD;
&#xD;
               -  Metastatic cancer to the lung&#xD;
&#xD;
          -  Extrathoracic metastases eligible if following criteria are met:&#xD;
&#xD;
               -  Sites are stable&#xD;
&#xD;
               -  Pulmonary sites are primary life-threatening sites&#xD;
&#xD;
               -  Evidence that study treatment may benefit the patient&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No germ cell tumor, leukemia, or lymphoma involving the lungs that is treatable with&#xD;
             systemic agents&#xD;
&#xD;
          -  No complete atelectasis due to high-grade airway obstruction&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.0 mg/dL&#xD;
&#xD;
          -  AST and ALT less than 1.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 40% by MUGA scan or echocardiogram&#xD;
&#xD;
          -  No unstable angina, congestive heart failure, or symptomatic arrhythmias&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 50% predicted&#xD;
&#xD;
          -  FVC and FEV1 at least 50% predicted&#xD;
&#xD;
          -  Resting oxygen saturation at least 90%&#xD;
&#xD;
          -  Exercise oxygen saturation at least 85%&#xD;
&#xD;
          -  Oxygen consumption greater than 50% predicted&#xD;
&#xD;
          -  No prior radiation pneumonitis&#xD;
&#xD;
          -  No asthma&#xD;
&#xD;
          -  No radiation-induced pulmonary damage&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No hypersensitivity to doxorubicin&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No congenital problems (e.g., cleft palate) or other anomalies that prevent tight fit&#xD;
             of a mouthseal&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy and recovered&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  Prior doxorubicin allowed if LVEF at least 40% by MUGA scan or echocardiogram&#xD;
&#xD;
          -  No prior mitomycin, bleomycin, or nitrosoureas&#xD;
&#xD;
          -  No other concurrent systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 12 months since prior radiotherapy to chest&#xD;
&#xD;
          -  No prior radiotherapy to more than 20% of total lung volume&#xD;
&#xD;
          -  Prior chest wall or primary breast radiotherapy allowed&#xD;
&#xD;
          -  Prior radioactive iodine allowed&#xD;
&#xD;
          -  No concurrent thoracic radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior total pneumonectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent experimental drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Schrump, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>lung metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

